This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. There are many individuals who experience one or more forms of chronic pain in their everyday life. In particular, there are many illnesses that fall under an umbrella called 'Chronic multi-symptom illness' (CMI). Such illnesses include, but are not limited to, fibromyalgia (FMS), chronic fatigue syndrome (CFS), irritable bowel syndrome (IBS), multiple chemical sensitivity (MCS), temporomandibular disorder (TMD), and Gulf War Veterans' Illnesses (GWVI). There are several investigators at the University of Michigan who do research with individuals who have one or more of these illnesses. This research study has been designed to develop a pool of individuals who are interested in participating in one or more of these studies. Many of these studies require that individuals be screened before they enter a research study. Screening visits generally contain one or more of the following items: a) history and physical exam, b) blood sampling, and c) completion of questionnaires. This project is aimed at creating a pool of persons who can be easily identified to participate in our research studies. Also, doing the screening procedures at this time may decrease the likelihood that they will need to be repeated at the time of recruitment for other studies. Individuals who want to be contacted with opportunities to participate in future CMI research at the University of Michigan may be able to participate in this study. There is no limit to the number of interested volunteers who can participate in the screening pool. These subjects will fall into one of two groups; 1) individuals with chronic multi-symptom illness or 2) healthy control subjects. To be included in the CMI patient group, subjects must be 18 years of age or older, must meet the established criteria for one or more of the CMIs and must be willing to be contacted in the future to participate in the screening process for an ongoing clinical trial. To be included in the healthy control group, subjects must be 18 years of age or older, must not meet the established criteria for one or more of the CMIs and must be willing to be contacted in the future to participate in the screening process for an ongoing clinical trial. Individuals within each group should have no other significant, chronic health problems requiring medications. Some of the studies involving CMI require that individuals not have other clinical conditions such as morbid obesity, autoimmune diseases, heart or lung problems (e.g. angina, congestive heart failure, COPD, chronic asthma), uncontrolled endocrine or allergic disorders (e.g. thyroid disease, diabetes requiring insulin), or cancer within the last 2 years. These requirements will be discussed at the time of the screening visit. In addition, individuals will be excluded from the pool if they: 1) have a psychiatric disorder involving a history of psychosis, 2) are deemed a current suicide risk, 3) have attempted suicide within two years of the study, or 4) they have a history of substance abuse within 2 years of the study.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
2M01RR000042-46
Application #
7376541
Study Section
Special Emphasis Panel (ZRR1-CR-8 (02))
Project Start
2006-04-05
Project End
2007-02-28
Budget Start
2006-04-05
Budget End
2007-02-28
Support Year
46
Fiscal Year
2006
Total Cost
$74,602
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Robarge, Jason D; Desta, Zereunesay; Nguyen, Anne T et al. (2017) Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer. Breast Cancer Res Treat 161:453-461
Crane, Natania A; Jenkins, Lisanne M; Bhaumik, Runa et al. (2017) Multidimensional prediction of treatment response to antidepressants with cognitive control and functional MRI. Brain 140:472-486
Hertz, Daniel L; Speth, Kelly A; Kidwell, Kelley M et al. (2017) Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients. Breast Cancer Res Treat 165:659-668
Hertz, D L; Kidwell, K M; Seewald, N J et al. (2017) Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer. Pharmacogenomics J 17:521-527
Kadakia, Kunal C; Kidwell, Kelley M; Seewald, Nicholas J et al. (2017) Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors. Breast Cancer Res Treat 164:411-419
Spengler, Erin K; Kleiner, David E; Fontana, Robert J (2017) Vemurafenib-induced granulomatous hepatitis. Hepatology 65:745-748
Heidemann, Lauren; Law, James; Fontana, Robert J (2017) A Text Searching Tool to Identify Patients with Idiosyncratic Drug-Induced Liver Injury. Dig Dis Sci 62:615-625
Law, Ian H; Alam, Osman; Bove, Edward L et al. (2016) Follow-Up of a Prospective Surgical Strategy to Prevent Intra-Atrial Reentrant Tachycardia After the Fontan Operation. Circ Arrhythm Electrophysiol 9:
Schrepf, Andrew; Harper, Daniel E; Harte, Steven E et al. (2016) Endogenous opioidergic dysregulation of pain in fibromyalgia: a PET and fMRI study. Pain 157:2217-2225
As-Sanie, Sawsan; Kim, Jieun; Schmidt-Wilcke, Tobias et al. (2016) Functional Connectivity is Associated With Altered Brain Chemistry in Women With Endometriosis-Associated Chronic Pelvic Pain. J Pain 17:1-13

Showing the most recent 10 out of 1380 publications